John Catanzaro
2 min readFeb 7, 2019

--

Coding / Non-Coding Mutations and Neoantigen Selection

Immune Surveillance and Evasion

Additional Cancer Hallmark Analytics Components

2019 John Catanzaro

As I mentioned in a previous post I will be covering the Cancer Hallmark Analytic and Immunocentric design in a prioritized order.

The first article (CHA1) was on genomic instability and mutations and of course I will expand on this topic further as their is much more to cover.

The next article will be on immune surveillance and evasion. After speaking with some of our team scientists there are other key features that will be added to the Hallmark schema not part of the original landscape that deserve their own integration in the model and I will elaborate on this further.

There will also be an article to follow on clarity on coding and noncoding mutations, a very misunderstood element in neoantigen selection.

As I mentioned in a previous post I will be covering the Cancer Hallmark Analytic and Immunocentric design in a prioritized order.

The first article (CHA1) was on genomic instability and mutations and of course I will expand on this topic further as their is much more to cover.

The next article will be on immune surveillance and evasion. After speaking with some of our team scientists there are other key features that will be added to the Hallmark schema not part of the original landscape that deserve their own integration in the model and I will elaborate on this further.

There will also be an article to follow on clarity on coding and noncoding mutations, a very misunderstood element in neoantigen selection.

Cancer Hallmark Analytics Prioritized

As I mentioned in a previous post I will be covering the Cancer Hallmark Analytic and Immunocentric design in a prioritized order.

The first article (CHA1) was on genomic instability and mutations and of course I will expand on this topic further as their is much more to cover.

The next article will be on immune surveillance and evasion. After speaking with some of our team scientists there are other key features that will be added to the Hallmark schema not part of the original landscape that deserve their own integration in the model and I will elaborate on this further.

There will also be an article to follow on clarity on coding and noncoding mutations, a very misunderstood element in neoantigen selection.

#genomics #scientists #genomesequencing #cancer #immunooncology #proteomics #proteins #peptides #neoantigens #mutations #genome #exome #molecularcoding

--

--

John Catanzaro

John A. Catanzaro is CEO of Neo7logix, a bioscience company that designs precision and personalized treatment designs. www.neo7logix.com